CN1946399A - 治疗精神分裂症和/或葡萄糖调节异常的方法 - Google Patents

治疗精神分裂症和/或葡萄糖调节异常的方法 Download PDF

Info

Publication number
CN1946399A
CN1946399A CNA2005800121147A CN200580012114A CN1946399A CN 1946399 A CN1946399 A CN 1946399A CN A2005800121147 A CNA2005800121147 A CN A2005800121147A CN 200580012114 A CN200580012114 A CN 200580012114A CN 1946399 A CN1946399 A CN 1946399A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
compound
halogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800121147A
Other languages
English (en)
Chinese (zh)
Inventor
C·P·史密斯
D·E·兰佩
B·博罗夫斯基
S·孔沙缪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CN1946399A publication Critical patent/CN1946399A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800121147A 2004-04-01 2005-04-01 治疗精神分裂症和/或葡萄糖调节异常的方法 Pending CN1946399A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01
US60/558,451 2004-04-01

Publications (1)

Publication Number Publication Date
CN1946399A true CN1946399A (zh) 2007-04-11

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800121147A Pending CN1946399A (zh) 2004-04-01 2005-04-01 治疗精神分裂症和/或葡萄糖调节异常的方法

Country Status (26)

Country Link
US (1) US20070129403A1 (https=)
EP (2) EP1734959B1 (https=)
JP (1) JP2007531730A (https=)
KR (1) KR20070010161A (https=)
CN (1) CN1946399A (https=)
AR (1) AR048197A1 (https=)
AT (1) ATE446754T1 (https=)
AU (1) AU2005231446A1 (https=)
BR (1) BRPI0509512A (https=)
CA (1) CA2561162A1 (https=)
CL (1) CL2009001605A1 (https=)
CY (1) CY1109734T1 (https=)
DE (1) DE602005017373D1 (https=)
DK (1) DK1734959T3 (https=)
DO (1) DOP2005000050A (https=)
ES (1) ES2334241T3 (https=)
GT (1) GT200500063A (https=)
IL (1) IL178168A0 (https=)
MX (1) MXPA06011222A (https=)
PA (1) PA8628601A1 (https=)
PL (1) PL1734959T3 (https=)
PT (1) PT1734959E (https=)
SI (1) SI1734959T1 (https=)
SV (1) SV2006002069A (https=)
TW (1) TW200602040A (https=)
WO (1) WO2005097122A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
JP2010506853A (ja) * 2006-10-12 2010-03-04 ゼノン・ファーマシューティカルズ・インコーポレイテッド 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
AU2010256541B2 (en) * 2009-06-03 2016-03-10 Marquette University Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MX2012004373A (es) 2009-10-14 2012-06-28 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol.
CA2788440A1 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
AU2020242978B2 (en) 2019-03-19 2025-10-02 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
NZ312577A (en) * 1995-07-27 1999-08-30 Hoechst Marion Roussel Inc Use of optionally substituted n-(pyrrol-1-yl)-pyridinamines as anticonvulsant agents
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
IL178168A0 (en) 2006-12-31
GT200500063A (es) 2005-10-14
MXPA06011222A (es) 2007-01-16
CL2009001605A1 (es) 2009-11-27
SV2006002069A (es) 2006-05-24
JP2007531730A (ja) 2007-11-08
AR048197A1 (es) 2006-04-05
EP2138176A1 (en) 2009-12-30
CY1109734T1 (el) 2014-09-10
DE602005017373D1 (de) 2009-12-10
DK1734959T3 (da) 2010-03-08
BRPI0509512A (pt) 2007-09-11
ES2334241T3 (es) 2010-03-08
EP1734959A2 (en) 2006-12-27
PA8628601A1 (es) 2006-05-16
ATE446754T1 (de) 2009-11-15
TW200602040A (en) 2006-01-16
AU2005231446A1 (en) 2005-10-20
PT1734959E (pt) 2009-12-24
DOP2005000050A (es) 2005-11-30
WO2005097122A3 (en) 2006-02-02
PL1734959T3 (pl) 2010-03-31
SI1734959T1 (sl) 2010-02-26
WO2005097122A2 (en) 2005-10-20
US20070129403A1 (en) 2007-06-07
KR20070010161A (ko) 2007-01-22
EP1734959B1 (en) 2009-10-28
CA2561162A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
CN1946399A (zh) 治疗精神分裂症和/或葡萄糖调节异常的方法
WO2009135091A1 (en) Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
CA2688327A1 (en) Methods and compositions for stimulating cells
JP2012508765A (ja) ファルネシルトランスフェラーゼ阻害剤を使用するタンパク症の治療
US20250122164A1 (en) N,n-dimethylamphetamine analogs for treating brain disorders
KR20160088886A (ko) 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 ｄ3 수용체 길항제로서의 크로모네 유도체
KR20210061349A (ko) 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도
EP3615022B1 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
WO2010132128A1 (en) Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
WO2025090928A9 (en) Compounds for treatment of neurodegenerative diseases
EP3510029A1 (en) Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
KR102784482B1 (ko) 신경퇴행성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
CN1510037A (zh) 山茱萸提取物、其提取方法以及在制备药物及保健品中的用途
JP2024547079A (ja) 運動ニューロン疾患及び神経筋接合部障害の処置のためのＮ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－アミンコハク酸塩及びその溶媒和物の使用
CN1917922A (zh) 1,2,3－取代中氮茚衍生物在治疗病理学脉络膜血管生成相关疾病中的用途
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
CN1662242A (zh) 用于治疗与神经营养蛋白相关和疾病的药物组合物
US20230364076A1 (en) Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
KR102640789B1 (ko) 질소 함유 헤테로고리 화합물 및 그의 용도
TW201441203A (zh) Ｎ－取代４－胺苯酚及對應醌亞胺
TWI879755B (zh) 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
KR20250047213A (ko) 질소 함유 헤테로고리 화합물의 다형체 및 그의 용도
WO2025054309A9 (en) Methods of identifying and treating patients having neurodegenerative disease based on plasma biomarker levels
CN111670041A (zh) 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
Xu et al. BDNF insufficiency exacerbates ALS progression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070411